Blueprint Medicines Appoints Habib Dable to its Board of Directors

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of Acceleron Pharma from 2016 to 2021, brings nearly 30 years of experience in strategic leadership, commercial growth and organizational scale across global pharmaceutical and emerging biotechnology companies.

“Habib’s experience leading global, complex organizations will be incredibly valuable as Blueprint Medicines drives our next phase of transformational growth,” said Kate Haviland, Chief Executive Officer. “We are thrilled to welcome his significant expertise and perspective to our board.”

“Blueprint Medicines has an impressive track record for a company of its size and age; even more impressive are the potential opportunities that lie ahead across development and commercialization,” said Mr. Dable. “I look forward to working with Blueprint’s high caliber team to execute on these opportunities and continue bringing the promise of precision medicine to broad patient populations.”

Mr. Dable joins Blueprint Medicines with significant leadership, growth and commercial experience gained during nearly 30 years in the biopharmaceutical industry. Most recently, as CEO at Acceleron, Mr. Dable generated more than $10 billion in shareholder value over his 5-year tenure as CEO before successfully transitioning to Merck following its acquisition. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility and geographic footprint, including President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA®; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. Recently, Mr. Dable served on the Board of Directors of the Biotechnology Innovation Organization (BIO). Mr. Dable received a B.B.A. in Marketing and Finance and his M.B.A. from the University of New Brunswick.

About Blueprint Medicines 

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.